These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 8425205)

  • 21. Mouse trophoblastic cell lines: II--Relationship between invasive potential and proteases.
    Sharma RK
    In Vivo; 1998; 12(2):209-17. PubMed ID: 9627804
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Augmented membrane type 1 matrix metalloproteinase (MT1-MMP):MMP-2 messenger RNA ratio in gastric carcinomas with poor prognosis.
    Caenazzo C; Onisto M; Sartor L; Scalerta R; Giraldo A; Nitti D; Garbisa S
    Clin Cancer Res; 1998 Sep; 4(9):2179-86. PubMed ID: 9748137
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer.
    Schmalfeldt B; Prechtel D; Härting K; Späthe K; Rutke S; Konik E; Fridman R; Berger U; Schmitt M; Kuhn W; Lengyel E
    Clin Cancer Res; 2001 Aug; 7(8):2396-404. PubMed ID: 11489818
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of matrix metalloproteinases, their inhibitors, and urokinase plasminogen activator in human meningiomas.
    Siddique K; Yanamandra N; Gujrati M; Dinh D; Rao JS; Olivero W
    Int J Oncol; 2003 Feb; 22(2):289-94. PubMed ID: 12527924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Type IV collagen induces matrix metalloproteinase 2 activation in HT1080 fibrosarcoma cells.
    Maquoi E; Frankenne F; Noël A; Krell HW; Grams F; Foidart JM
    Exp Cell Res; 2000 Dec; 261(2):348-59. PubMed ID: 11112341
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells.
    Rosanò L; Varmi M; Salani D; Di Castro V; Spinella F; Natali PG; Bagnato A
    Cancer Res; 2001 Nov; 61(22):8340-6. PubMed ID: 11719468
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Coordinate expression of membrane type-matrix metalloproteinases-2 and 3 (MT2-MMP and MT3-MMP) and matrix metalloproteinase-2 (MMP-2) in primary and metastatic melanoma cells.
    Ohnishi Y; Tajima S; Ishibashi A
    Eur J Dermatol; 2001; 11(5):420-3. PubMed ID: 11525948
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Suppression of type I collagenase expression by antisense RNA in melanoma cells results in reduced synthesis of the urokinase-type plasminogen activator receptor.
    Durko M; Brodt P
    Biochem Biophys Res Commun; 1998 Jun; 247(2):342-8. PubMed ID: 9642128
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas.
    Airola K; Karonen T; Vaalamo M; Lehti K; Lohi J; Kariniemi AL; Keski-Oja J; Saarialho-Kere UK
    Br J Cancer; 1999 May; 80(5-6):733-43. PubMed ID: 10360651
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transcriptional suppression of matrix metalloproteinase-2 gene expression in human astroglioma cells by TNF-alpha and IFN-gamma.
    Qin H; Moellinger JD; Wells A; Windsor LJ; Sun Y; Benveniste EN
    J Immunol; 1998 Dec; 161(12):6664-73. PubMed ID: 9862695
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma.
    Naka T; Kuester D; Boltze C; Schulz TO; Samii A; Herold C; Ostertag H; Roessner A
    Hum Pathol; 2008 Feb; 39(2):217-23. PubMed ID: 17949787
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modified proenzymes as artificial substrates for proteolytic enzymes: colorimetric assay of bacterial collagenase and matrix metalloproteinase activity using modified pro-urokinase.
    Verheijen JH; Nieuwenbroek NM; Beekman B; Hanemaaijer R; Verspaget HW; Ronday HK; Bakker AH
    Biochem J; 1997 May; 323 ( Pt 3)(Pt 3):603-9. PubMed ID: 9169591
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Directed migration of murine and human tumor cells to collagenases and other proteases.
    Terranova VP; Maslow D; Markus G
    Cancer Res; 1989 Sep; 49(17):4835-41. PubMed ID: 2547519
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of tissue inhibitor of the matrix metalloproteinases-2 expression on the growth and spontaneous metastasis of a human melanoma cell line.
    Montgomery AM; Mueller BM; Reisfeld RA; Taylor SM; DeClerck YA
    Cancer Res; 1994 Oct; 54(20):5467-73. PubMed ID: 7923181
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation.
    Quax PH; van Muijen GN; Weening-Verhoeff EJ; Lund LR; Danø K; Ruiter DJ; Verheijen JH
    J Cell Biol; 1991 Oct; 115(1):191-9. PubMed ID: 1918136
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Collagen dissolution by keratinocytes requires cell surface plasminogen activation and matrix metalloproteinase activity.
    Netzel-Arnett S; Mitola DJ; Yamada SS; Chrysovergis K; Holmbeck K; Birkedal-Hansen H; Bugge TH
    J Biol Chem; 2002 Nov; 277(47):45154-61. PubMed ID: 12192005
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasminogen activation in melanocytic neoplasia.
    Delbaldo C; Masouye I; Saurat JH; Vassalli JD; Sappino AP
    Cancer Res; 1994 Aug; 54(16):4547-52. PubMed ID: 8044805
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of matrix-degrading proteinases and their inhibitors secreted by human gynecological carcinoma cells.
    Miyagi E; Yasumitsu H; Hirahara F; Minaguchi H; Koshikawa N; Miyazaki K; Umeda M
    Jpn J Cancer Res; 1995 Jun; 86(6):568-76. PubMed ID: 7622422
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Physiological mechanisms for metalloproteinase activation.
    Murphy G; Ward R; Gavrilovic J; Atkinson S
    Matrix Suppl; 1992; 1():224-30. PubMed ID: 1480031
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metalloproteinases in tumor progression: the contribution of MMP-9.
    Himelstein BP; Canete-Soler R; Bernhard EJ; Dilks DW; Muschel RJ
    Invasion Metastasis; 1994-1995; 14(1-6):246-58. PubMed ID: 7657517
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.